The FDA has cleared Teleflex to market its ARROW VPS G4 Device, which could be released in the U.S. during the second quarter of the year. The system is said to be the only such device designed to pinpoint the exact site of the lower 1/3 of the vena cava and cavo-atrial junction using micro-Doppler ultrasound combined with advanced algorithms and intravascular ECG.

Full Story:
RTT News

Related Summaries